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INTRODUCTION
TRANSPLANTATION OF selected cell populations is cur-rently being investigated to regenerate and engineer
a number of tissues in the body. In tissue engineering and
related therapeutic strategies, cells are often delivered
within three-dimensional constructs designed to inform
cell function and/or overall tissue shape, as well as pro-
vide space for efficient delivery of an appropriate cell
number. However, clinical application of cell-based ther-
apies is limited, as the transplanted cells often lose func-
tion or die after delivery to the recipient and this is es-
pecially notable in the case of cells with high metabolic
activity, such as hepatocytes.1,2 The massive cell loss that
occurs within several days of transplantation is likely due
to inadequate availability of nutrients for cells in the in-
terior of delivery devices. Oxygen supply is particularly
limiting, as cells more than approximately 200 mm from
a blood vessel suffer from hypoxia and die.3,4 The vas-
culature of the host will eventually penetrate macrop-
orous matrices utilized for cell delivery via the process
of angiogenesis, by which new blood vessels sprout from
those that already exist and grow into undervascularized
regions nearby. This natural angiogenic response is, how-
ever, insufficient to support the larger cell masses re-
quired to provide therapeutic support, and therefore likely
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ABSTRACT
A developing therapy for complete or partial loss of function in various tissues and organs involves
transplanting an appropriate cell population, capable of compensating for the existing deficiencies.
Clinical application of this type of strategy is currently limited by the death or dedifferentiation of
the transplanted cells after delivery to the recipient. A delay in thorough vascularization of the im-
plant area creates an environment low in oxygen and other nutrients, and likely contributes to the
initial death of transplanted cells. We have addressed this problem by sustained delivery of vascu-
lar endothelial growth factor (VEGF), an initiator of angiogenesis, from a porous polymer matrix
utilized simultaneously for cell delivery. As expected from previous studies, VEGF delivered from
these constructs elicited an enhanced angiogenic response over a 2-week period when implanted
subcutaneously in SCID mice. Hepatocytes implanted using VEGF-containing matrices demon-
strated significantly greater survival after 1 week in vivo as compared with cells implanted on ma-
trices without growth factor. The results of this study therefore indicate that enhancing vascular-
ization in the location of transplanted cells promotes their survival. In addition, this delivery system
may be used in future studies to directly promote cell survival and function by also providing growth
factors specific to the transplanted cells.
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contributes to the limited applicability of these applica-
tions.
Extensive studies of the angiogenic process have
yielded knowledge of the identity and function of criti-
cal molecules involved in this phenomenon, making it
possible to manipulate blood vessel sprouting through de-
livery of appropriate factors. One of the key regulators
of angiogenesis is vascular endothelial growth factor
(VEGF), a potent endothelial cell-specific mitogen and
chemoattractant5 produced by a variety of cell types in
response to low oxygen levels.6 A number of studies fo-
cusing on VEGF, both in vitro and in vivo, have eluci-
dated mechanisms through which VEGF induces blood
vessel sprouting.6,7 It has also been found that defects in
spatial or temporal regulation of VEGF production are
associated with pathological conditions (e.g., cancerous
tumor growth, disorders of retina vascularization), indi-
cating the importance of delivering this molecule only
where and when it is needed in therapeutic applications.8
Other important factors to consider when delivering
VEGF are its heparin-binding property and its short half-
life in the body, because these will largely determine the
area over which delivered growth factor may elicit a re-
sponse. Together, these characteristics suggest that con-
trolled, localized delivery may be the best approach to
enhance vascularization when utilizing VEGF. With this
type of strategy it is possible to address spatial and tem-
poral requirements, as well as growth factor stability, be-
cause it may be protected from denaturation within the
delivery device. Successful delivery of bioactive mole-
cules from polymer constructs has been demonstrated for
a variety of growth factors,9–13 and studies looking
specifically at VEGF have demonstrated improved vas-
cularization of the delivery construct.14–16
In the present study, we hypothesized that delivery of
VEGF from a polymer scaffold utilized to simultaneously
deliver a cell population would speed vascularization of
the construct, and therefore enhance cell survival. Hepa-
tocytes were selected as a model cell type because they
are desirable for tissue-engineering applications2,17 but dif-
ficult to effectively transplant.1,18 The native architecture
of the liver is such that hepatocytes are rarely observed
more than two cell diameters from a functional blood ves-
sel, emphasizing their high level of metabolic activity and
particular dependence on transport of oxygen and other nu-
trients. Enhancing angiogenesis and improving the envi-
ronment around the transplanted hepatocytes may there-
fore promote their survival after transplantation.
MATERIALS AND METHODS
Matrix fabrication
Scaffolds were formed by a modification of a previ-
ously published process,19,20 which involves fabricating
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poly(lactide-co-glycolide) (PLG) into microspheres be-
fore forming scaffolds from the polymer. Microspheres
were made with 85:15 PLG (Resomer RG858; Boehringer
Ingleheim; Ingleheim, Germany) via a standard double-
emulsion process.21 In brief, a 5% (w/v) solution of PLG
in ethyl acetate (Sigma, St. Louis, MO) was combined
with distilled water in a test tube, and this two-phase mix-
ture was sonicated (Vibracell; Sonics & Materials, New-
town, CT) to yield a single emulsion. An equal volume
of an aqueous solution containing 1% poly(vinyl alco-
hol) (PVA, MW 25,000, 88% hydrolyzed; Polysciences,
Warrington, PA) and 7% ethyl acetate was added to the
single emulsion, and the resulting solution was vortexed
(Vortex Genie; VWR, West Chester, PA) to yield the
double emulsion. This double emulsion was immediately
transferred to 200 mL of a rapidly stirring aqueous solu-
tion of 0.3% PVA–7% ethyl acetate. After allowing the
ethyl acetate to evaporate over a 3-h period, the micros-
phere-containing solution was filtered to retrieve the mi-
crospheres, which were then rinsed with water and
lyophilized.
For each matrix, 3 mg of microspheres was combined
with 10 mg of vascular endothelial growth factor (VEGF)
(Intergen, Purchase, NY) dissolved in 150 mL of a 0.1%
MVM alginate (Pronova, Oslo, Norway) solution. This
mixture was lyophilized to form a powder, combined with
50 mg of NaCl (sieved to yield a particle diameter be-
tween 250 and 425 mm), and pressed in a 4.76-mm-di-
ameter die to create a 1.5-mm-thick disk. The PLG was
gas foamed by subjecting the disks to CO2 (800 lb/in2)
for 24 h, followed by a rapid reduction of pressure to am-
bient. The NaCl was leached from matrices by incuba-
tion in 0.1 M CaCl2 for 16 h before use in experiments.
Blank control matrices were manufactured by omission
of VEGF from the processing protocol.
Matrix characterization
The size and volume distribution of microspheres were
measured with a ZM Coulter counter (Beckman Coulter,
Fullerton, CA). Imaging of representative microspheres
and porous matrices was performed with a scanning elec-
tron microscope (ISI-DS 130; Topcon Technologies,
Pleasanton, CA) on samples that were dried and sputter
coated with gold (Desk II; Denton Vacuum, Cherry Hill,
NJ).
VEGF release kinetics
To determine the incorporation efficiency and release
kinetics of VEGF from the porous matrices, receptor-
grade 125I-labeled human VEGF (100 mCi/mg) (Bio-
medical Technologies, Stoughton, MA) was utilized as a
tracer. Approximately 1 mCi of labeled VEGF was in-
corporated into each matrix, along with the 10 mg of un-
labeled VEGF as described above. To determine the re-
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lease of VEGF, six matrices prepared with the radiola-
beled VEGF were placed in 3 mL of phosphate-buffered
saline (PBS; GIBCO, Grand Island, NY) and maintained
at 37°C. At various times, the matrices were removed
from the PBS, and the radioactivity remaining in each
matrix was measured with a g counter. The amount of
VEGF released from the matrices was determined at each
time point by counting the removed samples in a g
counter and comparing the result with the total 125I-la-
beled VEGF measured in the matrices before they were
placed in PBS.
Hepatocyte isolation
Hepatocytes were isolated from adult male Lewis rats
(150–200 g; Charles River Laboratories, Wilmington,
MA) by a modification of the original Seglen two-step
collagenase perfusion procedure.22 Briefly, the liver
was perfused via the portal vein, first with calcium-free
buffer (142 mM NaCl, 7 mM KCl, 20 mM HEPES, pH
7.4, 37°C) for 10 min, followed immediately by colla-
genase-containing buffer (142 mM NaCl, 7 mM KCl,
20 mM CaCl2, 20 mM HEPES, collagenase type 2 [0.5
mg/mL; Worthington Biochemical, Lakewood, NJ], pH
7.4, 37°C). Perfusion with the collagenase-containing
buffer was continued for 7–10 min, until the liver tis-
sue was sufficiently disrupted as determined by visual
inspection. The perfused liver was then placed in ice-
cold William’s Medium E, and dissociation of the cells
was performed by removing the liver capsule and gen-
tly shaking the hepatocytes free from the remaining liver
matrix. This cell suspension was then filtered through
a 400-mm Nytex mesh (Sefar America, Tetko, Depew,
NY) to remove large debris. The cell yield per liver was
1–2 3 108 and the initial percentage of viable cells was
80–90%. To further purify the cell population and re-
move cellular debris, density gradient centrifugation us-
ing Percoll (Sigma) was performed. The collected he-
patocytes, which had a total cell viability greater than
90%, were then placed on ice and immediately used in
experiments.
SCID mouse implants
Matrices (n 5 3) from each condition were implanted
in subcutaneous pockets (two per animal) on the dorsal
region of 7- to 9-week-old male SCID mice (cb17/SCID)
(Taconic, Germantown, NY). A 1.5-cm longitudinal in-
cision was made on each animal’s back and one implant
was then placed between the skin and muscle layers on
either side of the incision. The incision was closed with
two interrupted sutures and covered with tissue adhesive
(Mastisol; Ferndale Laboratories, Ferndale, MI) to help
seal the opening. All National Institutes of Health (NIH,
Bethesda, MD) guidelines for the care and use of labo-
ratory animals were observed.22a
ENHANCED VASCULARIZATION TO PROMOTE CELL SURVIVAL
For conditions including transplanted cells, immedi-
ately before matrix implantation 1 3 106 hepatocytes
were suspended in 25 mL of a 1:1 mixture of William’s
Medium E and growth factor-reduced Matrigel (BD Bio-
sciences Discovery Labware, Bedford, MA) and allowed
to absorb into the polymer matrix for 5 min. The cell-
seeding efficiency was determined by counting the cells
remaining in the dish after this absorption period.
Mice were killed and matrices retrieved at 7 and 14
days for vascularization studies, and at 3 and 7 days for
hepatocyte studies. The matrices were dissected out of
the tissue and immediately placed into 10 mL of buffered
zinc–formalin, where they remained for 24 h at 4°C. The
zinc–formalin was then exchanged for 70% ethanol and
samples were stored at 4°C until they were embedded in
paraffin by the University of Michigan, School of Den-
tistry, Histology Core (Ann Arbor, MI).
Histology staining
Paraffin-embedded matrices were cut into 5-mm sec-
tions and placed on glass slides for histological analysis.
Tissue sections were either stained with Gill’s 3 hema-
toxylin (Sigma) and aqueous eosin Y solution (Sigma) to
visualize overall tissue morphology, or immunostained
with antibodies raised against mouse CD31 (clone MEC
13.3) (BD Biosciences Pharmingen, San Diego, CA) to
detect endothelial cells and mouse vasculature.
To immunostain tissue sections, the slides were first
deparaffinized and rehydrated, and then washed in 3%
H2O2 (Sigma) in PBS to quench endogenous peroxidase
activity. To improve antigen exposure the slides were
treated with citrate buffer (Biocare Medical, Walnut
Creek, CA). Nonspecific antibody interactions were
blocked by incubating the slides in Terminator blocking
solution (Biocare Medical) for 10 min at 25°C. Anti-
mouse CD31 primary antibody, diluted in Van Gogh
Green antibody diluent (Biocare Medical), was then in-
cubated with the sections for 1.5 h at 25°C. Bound pri-
mary antibody was then detected with a biotinylated sec-
ondary antibody, followed by a streptavidin–horseradish
peroxidase (HRP) conjugate (both from Biocare Med-
ical). The substrate added for the HRP reaction was 3,39-
diaminobenzidine (DAB) (Zymed, South San Francisco,
CA). Finally, sections were lightly counterstained with
hematoxylin.
Histological analysis
Tissue sections were visualized and photographed with
an E-800 light microscope (Nikon, Melville, NY). Three
samples from each condition, with six sections from each
sample, were analyzed manually and digitally with NIH
Image software (developed by the U.S. National Insti-
tutes of Health). Blood vessels present in the implants
were analyzed for their total number, and were identified
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by their defined lumens in CD31-stained tissues at 3200
magnification.
For conditions utilizing transplanted hepatocytes, the
total number of engrafted hepatocytes in each section was
manually counted at 3200 magnification. Engrafted he-
patocytes were identified by their large size, large and
spherical nuclei, and distinct cytoplasmic staining as de-
scribed in a number of published reports.2,23,24
Statistical analysis
The Student t test (one-tailed) was utilized to analyze
the statistical significance of differences between data
from VEGF and control conditions for both blood vessel
and engrafted hepatocyte quantification, with p # 0.05
taken as significant. InStat version 2.01 software (Graph-





Microspheres fabricated for use in matrix preparation
(Fig. 1A) had a number average diameter of 2.3 mm, and
a volume average diameter of 20 mm (Fig 1B). Matrices
formed with microspheres had an interconnected open
porous structure (Fig. 2A). The efficiency of VEGF in-
corporation was measured to be 36 6 1%. In vitro, this
system exhibits a release profile in which 25% of the in-
corporated growth factor is released within 3 days, fol-
lowed by a subsequent constant release of approximately
1%/day for the duration of the study (Fig. 2B).
Implant vascularization
Matrices processed to release VEGF, and control ma-
trices containing no growth factor, were implanted into
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FIG. 1. Microsphere characterization. (A) Scanning electron micrograph of a PLG microsphere, original magnification, 32500.
(B) Size distribution of PLG microspheres as a function of each size’s fraction of the total microsphere volume. 85:15 PLG mi-
crospheres demonstrate a number average particle diameter of 2.3 mm, and a volume average diameter of 20 mm.
SCID mice for a period of 7 or 14 days to evaluate the
ability of delivered VEGF to enhance matrix vascular-
ization. On retrieval the samples were stained for the
presence of murine CD31 antigen to identify capillary
blood vessels. A greater blood vessel density was pres-
ent in VEGF-containing scaffolds than in control scaf-
folds at both time points. The enhanced vascularity was
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more pronounced at the 7-day time point (Fig. 3A and
C) than at 14 days, as vessel density under all conditions
had increased over time (Fig. 3B and D). Quantification
confirmed these observations, as blood vessel density was
nearly an order of magnitude greater in VEGF-releasing
samples after 7 days, as compared with control samples
(Fig. 4). After 14 days the VEGF conditions were ob-
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FIG. 2. Matrix characterization. (A) Scanning electron micrograph of PLG microsphere matrices containing 5 wt% alginate;
original magnification, 3100. (B) VEGF release from PLG matrices. Values represent means and standard deviation (n 5 6).
FIG. 3. VEGF delivery enhances blood vessel formation in implanted matrices as observed in tissue sections immunostained
for mouse CD31 antigen. Blood vessels can be observed within the matrices as early as 7 days [(A) control; (C) VEGF] after
implantation. After both 7 days and 14 days [(B control; (D) VEGF] many more positively stained vessels are present under
VEGF-releasing conditions than under control conditions without growth factor. Original magnification, 3400.
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served to yield approximately twice the number of blood
vessels as control samples, although no qualitative dif-
ferences in vessel diameter were observed between
VEGF and control conditions.
Hepatocyte survival
To determine whether this method of improving vas-
cularization would enhance the local environment and
promote survival of transplanted cells, primary rat hepa-
tocytes were seeded onto either VEGF-containing or
blank control matrices and delivered subcutaneously to
SCID mice. Hepatocytes were seeded with an efficiency
of 53 6 8%, and their survival was assessed 3 and 7 days
after implantation. Observation of hematoxylin and eosin
(H&E)-stained sections revealed that the majority of he-
patocytes under both VEGF and control conditions re-
mained alive after 3 days in vivo (Fig. 5A and C). How-
ever, a difference in viable hepatocyte number became
apparent at the day 7 time point. The total number of he-
patocytes existing in control scaffolds had declined, and
many of the remaining cells lacked evidence of a nucleus,
indicating a loss of viability. Hepatocytes exhibiting a
healthy-appearing morphology were more prevalent in
VEGF-releasing samples, where overall hepatocyte den-
sity appeared similar to day 3 (Fig. 5B and D), and the
majority of these surviving cells were located near in-
growing blood vessels. Quantification of transplanted cell
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FIG. 4. Density of blood vessels in PLG matrices implanted
into SCID mice. Blood vessels were manually counted at 3200
magnification in tissue sections stained with antibodies for the
presence of mouse CD31. Samples included control matrices
without any growth factor (open columns) and matrices releas-
ing VEGF (solid columns). The number of blood vessels
counted in VEGF samples was significantly greater (p , 0.05)
than that observed in control samples after 7 and 14 days. Re-
sults are expressed as mean values plus SEM (n 5 3).
FIG. 5. H&E-stained sections of matrices used for hepatocyte transplantation. Hepatocytes were seeded onto matrices, im-
planted into SCID mice, and retrieved after 3 days [(A) control; (C) VEGF] and 7 days [(B) control; (D) VEGF] days. Original
magnification, 3400.
survival confirmed these observed trends, as there was
no measurable difference between VEGF and control
conditions in the fraction of hepatocytes surviving after
3 days in vivo, with approximately 70% of cells in the
matrices remaining alive. To clearly indicate the signifi-
cantly enhanced hepatocyte survival measured under
VEGF-releasing conditions after 7 days (p , 0.05), the
number of living cells at this time point has been nor-
malized to the number of living cells on day 3 (Fig. 6).
The number of hepatocytes surviving under VEGF con-
ditions remained essentially constant from day 3 to day
7, whereas survival of their counterparts under control
conditions declined to less than 50% of the day 3 value
during the same time interval.
To confirm that simultaneous hepatocyte delivery did
not alter matrix vascularity, histological sections of ma-
trices retrieved 7 days postimplantation were stained for
CD31 to quantify induced blood vessel density, and the
values were statistically similar to those for matrices im-
planted without cells (VEGF, 24 6 10 vessels/mm2; con-
trol, 2 6 1 vessels/mm2).
DISCUSSION
The results of this study indicate that sustained, local-
ized delivery of VEGF from a polymer matrix enhances
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the formation of blood vessels within the construct, and
that the extent of vascularization is similar with and with-
out simultaneous delivery of cells. In addition, enhanc-
ing vascularization of the device through VEGF delivery
promotes the survival of these transplanted cells. This
system may find utility in cell-based therapies, and may
be extended to directly manipulate the transplanted cells
through delivery of additional growth factors specific to
the cells of interest.
Delivery of VEGF from a cell transplantation matrix
can significantly enhance blood vessel formation in the
matrix. This significant enhancement of vascularization
in VEGF-releasing matrices over the course of 2 weeks
was anticipated from previous studies.15,25 However, in
these earlier studies blood vessels were identified by their
morphology in hematoxylin and eosin-stained sections.
Here we have demonstrated that definitive blood vessel
identification via endothelial cell-specific CD31 im-
munostaining gives trends similar to those determined by
hematoxylin and eosin staining. The values for the mea-
sured vessel densities, under both VEGF and control con-
ditions, were lower in this study than in our previous re-
ports. This difference is related to a modification of the
scaffold fabrication process. Matrices used in earlier
VEGF delivery studies were composed of granular PLG,
as opposed to the PLG microspheres used here, and when
these granular-based matrices were sectioned for histo-
logical analysis the center portion of each section often
became damaged or lost completely. Blood vessel num-
ber could then be quantified only in outer regions of the
matrices, which are more heavily vascularized. This led
to inflation of values for blood vessel density. Matrices
formed with microspheres, on the other hand, retain their
integrity during histological processing, making them su-
perior for studies of vascularization as they allow for
more accurate quantification of blood vessels throughout
the entire section.
The increased blood vessel density resulting from
VEGF delivery was clearly greater than under control
conditions at the 1- and 2-week time points. The trend
observed for induction of vessel growth is not surprising
because a majority of the incorporated VEGF is released
within 2 weeks, and the majority of that release occurs
in the first 2–3 days. This result is also desirable, as our
aim is to rapidly modify the environment within the ma-
trix and then cease to influence the system so that a nat-
ural tissue, in physiologic balance with the host, can de-
velop. Employing a localized delivery system for the
growth factor generally minimizes the overall effect on
the host, as it allows for enhancing blood vessel forma-
tion where necessary, while eliminating the risk of toxic
side effects26 and unwanted blood vessels developing at
other sites in the body. Localized, as opposed to systemic,
delivery also makes it possible to deliver smaller amounts
of growth factor to elicit the desired response. Sustained
release is a significant aspect of the type of system pre-
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FIG. 6. Quantification of hepatocyte survival after transplan-
tation. Hepatocytes were counted in histological sections at
3200 magnification after 3 and 7 days in vivo. Data presented
are normalized to the number of live cells present under each
condition on day 3. On day 3, hepatocytes under control (open
columns) and VEGF (solid columns) conditions exhibited ap-
proximately equal hepatocyte viability. However, VEGF-re-
leasing matrices exhibited significantly greater hepatocyte sur-
vival at the day 7 time point as compared with control (p ,
0.05). Results are expressed as mean values plus SEM for two
separate experiments, each with n 5 3.
sented here, as previous studies with this system have
demonstrated that bolus injection of an equivalent
amount of VEGF into a blank matrix at the time of im-
plantation leads to no significant improvement in vascu-
larization.16 Importantly, when hepatocytes were trans-
planted on VEGF-releasing matrices, the trend of
enhanced blood vessel ingrowth was essentially identical
to that observed when cells were not included. Thus, the
transplanted cell mass neither inhibited the ability of ves-
sels to penetrate the matrix, nor produced enough VEGF
to further enhance the vascular response. These are im-
portant findings, indicating that this system for promot-
ing vascularization can be utilized in conjunction with
cell delivery, and that it provides an added stimulus be-
yond that produced by the cells themselves. Differences
in blood vessel diameter between VEGF and control con-
ditions were not observed. This is not surprising, as
VEGF is primarily an inducer of vascularization and
other factors are likely required to promote formation of
larger and more mature vessels.16
Enhanced vascularization induced by VEGF delivery
correlated with significantly greater survival of implanted
hepatocytes after 1 week, as compared with control con-
ditions under which VEGF was not simultaneously de-
livered with the cells. There was not a detectable differ-
ence in hepatocyte survival at an intermediate 3-day time
point, but a difference was not necessarily expected then,
as the growth factor would not be expected to enhance
new blood vessel ingrowth through the majority of the
scaffold over this initial interval. However, after 7 days
in vivo, the percentage of surviving hepatocytes under
VEGF-releasing conditions was approximately twice 
that of hepatocytes implanted on blank control matrices.
Other investigators have similarly demonstrated that in-
creasing the vascularity of the transplant area, before he-
patocyte implantation, can enhance engraftment of the
cells,17,24,27,28 as can implantation in highly vascularized
sites such as the small intestinal mesentery.18,29 Utiliz-
ing VEGF as a proangiogenic stimulus may additionally
enhance oxygen delivery to the cells, because of the va-
sodilation it induces and the leakiness of vessels exposed
to VEGF. Together, the results of our current report and
others clearly illustrate the value of using proangiogenic
interventions in conjunction with hepatocyte transplanta-
tion.
In this work, we enhanced transplanted hepatocyte sur-
vival indirectly, by delivering VEGF to manipulate the
response of endothelial cells surrounding the implanted
construct. Previous studies have demonstrated that 
surgical interventions (e.g., partial hepatectomy, por-
tal–caval shunting) can also dramatically enhance he-
patocyte engraftment and proliferation,29,30 and these 
processes may directly influence hepatocyte survival by
altering the availability of blood-borne growth factors for
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hepatocytes. These surgical procedures could potentially
be replaced by using the system described in this article
for the controlled delivery of survival factors present in
the portal circulation that act directly to enhance hepato-
cyte survival and function (e.g., epidermal growth factor,
hepatocyte growth factor).2 In the context of the current
study, delivery of these factors may prove particularly
important in promoting survival during the initial days
after transplantation, before VEGF is able to promote vas-
cularization at the implant site. Sequences of growth fac-
tors,16 or plasmid DNA,31 can also be readily delivered
with this system.
In summary, we have developed a system capable of
simultaneously delivering growth factors and cell popu-
lations with potential therapeutic applications. This sys-
tem may be utilized in future studies with other growth
factors, or combinations of growth factors, and other cell
types to enhance the survival and function of transplanted
cells.
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